|
Valoración de DCF de Pharmacyte Biotech, Inc. (PMCB)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
PharmaCyte Biotech, Inc. (PMCB) Bundle
¡Descubra el verdadero potencial de Pharmacyte Biotech, Inc. (PMCB) con nuestra calculadora DCF avanzada! Ajuste los supuestos esenciales, explore varios escenarios y evalúe cómo estos cambios afectan la valoración de Pharmacyte Biotech, Inc. (PMCB), todo dentro de una conveniente plantilla de Excel.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA | -3.8 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Depreciation | 3.8 | 3.6 | 4.4 | 6.5 | .0 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
EBIT | -7.7 | -3.6 | -4.4 | -6.5 | .0 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Total Cash | .9 | 2.2 | 85.4 | 68.0 | 50.2 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Accounts Payable | .2 | .2 | .2 | .1 | .4 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -7.7 | -3.6 | -4.2 | -6.5 | .0 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -3.6 | .0 | .2 | -.1 | .3 | -.4 | .0 | .0 | .0 | .0 |
WACC, % | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 |
PV UFCF | ||||||||||
SUM PV UFCF | -.4 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | 0 | |||||||||
Net Debt | -50 | |||||||||
Equity Value | 50 | |||||||||
Diluted Shares Outstanding, MM | 10 | |||||||||
Equity Value Per Share | 5.20 |
What You Will Get
- Comprehensive Financial Model: PharmaCyte Biotech’s actual data supports accurate DCF valuation.
- Complete Forecast Control: Modify revenue growth, profit margins, WACC, and other essential parameters.
- Real-Time Calculations: Automatic updates ensure you receive immediate feedback as you adjust inputs.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation presentations.
- Flexible and Reusable: Designed for adaptability, allowing for repeated application in detailed forecasting.
Key Features
- Customizable Clinical Trial Parameters: Adjust vital inputs such as patient enrollment rates, treatment efficacy, and trial duration.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and various financial metrics.
- High-Precision Accuracy: Incorporates PharmaCyte's actual financial data for precise valuation results.
- Effortless Scenario Analysis: Evaluate different clinical outcomes and strategies with ease.
- Efficiency Booster: Streamline the process of developing intricate valuation models without starting from scratch.
How It Works
- Step 1: Download the prebuilt Excel template featuring PharmaCyte Biotech, Inc.'s (PMCB) data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Update your forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including PharmaCyte Biotech, Inc.'s (PMCB) intrinsic value.
- Step 5: Utilize the outputs to make informed investment decisions or create reports.
Why Choose This Calculator for PharmaCyte Biotech, Inc. (PMCB)?
- User-Friendly Interface: Tailored for both newcomers and seasoned professionals.
- Customizable Inputs: Adjust parameters effortlessly to suit your financial analysis.
- Real-Time Valuation: Monitor immediate updates to PharmaCyte’s valuation as you tweak inputs.
- Preloaded Financial Data: Comes with PharmaCyte’s actual financial metrics for swift evaluations.
- Relied Upon by Experts: Utilized by investors and analysts for strategic decision-making.
Who Should Use PharmaCyte Biotech, Inc. (PMCB)?
- Investors: Gain insights into cutting-edge biotech innovations to make informed investment choices.
- Biotech Analysts: Streamline your research with comprehensive data on PharmaCyte's pipeline and market potential.
- Consultants: Easily tailor presentations and reports to highlight PharmaCyte's unique offerings.
- Healthcare Enthusiasts: Expand your knowledge of biotechnology and its impact on patient care through real-life case studies.
- Educators and Students: Utilize PharmaCyte's advancements as a case study in biotech and pharmaceutical courses.
What the Template Contains
- Preloaded PMCB Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.